Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2 Pain, Intractable 1 Mucositis 1 Leukemia 1 Inflammatory Bowel Diseases 1 Diverticulitis 1 Diverticular Diseases 1 Colonic Neoplasms 1 Cancer Pain 1 Breast Neoplasms 1 Breast Cancer Female 1 Breakthrough Pain 1 Bone Marrow Failure Disorders 1 Bites and Stings 1 Anemia, Aplastic 1 Agnosia 1 Acute Pain 1

Interventions

pembrolizumab 3 enzalutamide 2 blinatumomab 2 abiraterone 2 Stents 2 Neoadjuvant Therapy 2 Immune Checkpoint Inhibitors 2 Cytochrome P-450 Enzyme System 2 soybean oil, phospholipid emulsion 1 durvalumab 1 dostarlimab 1 cemiplimab 1 camrelizumab 1 atezolizumab 1 Surgical Procedures, Operative 1 Surgical Instruments 1 Radiotherapy, Conformal 1 Radiotherapy 1 Passive Cutaneous Anaphylaxis 1 Palliative Care 1 Nephrotomy 1 Nephrostomy, Percutaneous 1 N,N-dicyclohexyl-isoborneol-10-sulfonamide 1 Morphine 1 Lidocaine 1 Levobupivacaine 1 Immunotherapy 1 Hydroxyurea 1 Etoposide 1 Etanercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Bites and Stings × Passive Cutaneous Anaphylaxis × Clear all

NCT03165383 2017-05-24

TAP

Rajiv Gandhi Cancer Institute & Research Center, India

Phase NA Completed

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon ⚡